CliffBio
small molecule

ALEVE

NAPROXEN SODIUM

Loss of exclusivity—loss of exclusivity
CompanyBayer Healthcare →See this company's full patent-cliff portfolio

Drug detail

Brand nameALEVE
Active ingredientNAPROXEN SODIUM
Strength220MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJanuary 1994
Marketing statusOTC

More from Bayer Healthcare

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.